Back to results
US 2024/0173400 A1Published application
Herpes simplex virus vaccine
AssigneeModernaTX, Inc.
InventorsGiuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro
Life of this patent
Estimating the term…
Abstract
Provided herein are immunogenic compositions comprising mRNA encoding herpes simplex virus polypeptides, as well as methods of using the immunogenic compositions.
Claims17
-71. (canceled)
A method of inducing an herpes simplex virus (HSV) antigen-specific immune response in a subject, the method comprising administering to the subject a composition comprising:
- (a) a messenger ribonucleic acid (mRNA) polynucleotide having an open reading frame (ORF) encoding at least one HSV antigenic polypeptide, and
- (b) a lipid nanoparticle,
- wherein the lipid nanoparticle comprises 40-60 mol % ionizable cationic lipid, 5-15 mol % neutral lipid, 30-50 mol % cholesterol, and 0.5-3 mol % polyethylene glycol (PEG)-modified lipid,
- to produce an HSV antigen-specific immune response in the subject.
1 more element
Dependencies are inferred from the claim text.